Year: 2016
Type: review
Abstract: The quality of care can be improved by the development and implementation of evidence-based treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them.This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators.There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of long-acting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.
Source: European Respiratory Journal
Institutions: Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Vall d'Hebron Hospital Universitari, Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, German Center for Lung Research, Hôpital Cochin, Université Paris Descartes, Mucoviscidose et bronchopathies chroniques : biopathologie et phénotype cliniques, Royal Devon and Exeter Hospital, Unidade Local de Saúde de São José, Hospital de Santa Marta, Universidade Nova de Lisboa, Federal Medical-Biological Agency, Tampere University, Seinäjoen Keskussairaala, University of Tampere, Umeå University, University Hospital Olomouc, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: chronic obstructive pulmonary disease, COPD management guidelines, national clinical practice guidelines, guideline comparison, risk stratification, disease severity, clinical phenotype, long-acting bronchodilators, inhaled corticosteroids, theophylline, mucolytic agents, comorbidities, treatment goals, Europe, Russia
Open Access status: hybrid
Funders: Novartis, Novartis Pharma
OpenAlex ID: W2265301060
